

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 3,074 | 2,881 | 2,773 | 3,250 | 2,840 |
| Total Expenses | 3,090 | 3,287 | 3,103 | 3,478 | 3,266 |
| Profit Before Tax | -16 | -420 | -624 | -411 | -568 |
| Profit After Tax | -57 | -472 | -621 | -279 | -297 |
| Operating Profit After Depreciation | 238 | -101 | -28 | 71 | -177 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,256 | 4,169 | 4,167 | 4,415 | 4,119 |
| Total Non Current Assets | 5,670 | 5,576 | 5,475 | 5,654 | 5,349 |
| Total Current Assets | 2,465 | 2,073 | 2,208 | 2,589 | 2,425 |
| Total Assets | 8,135 | 7,649 | 7,683 | 8,243 | 7,774 |
| Total Shareholder's Fund | 4,353 | 3,359 | 3,354 | 3,849 | 3,376 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -22 | 219 | 153 | 413 | -287.32 |
| Net Cash Used In Investing Activities | -780 | -138 | -118 | -204 | 1,471.05 |
| Net Cash Used In Financing Activities | 409 | 334 | -315 | -71 | -1,170.82 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,457 | 1,195 | 1,139 | 1,410 | 1,028 |
| Total Expenses | 1,469 | 1,603 | 1,417 | 1,594 | 1,509 |
| Profit Before Tax | -12 | -422 | -513 | -184 | -623 |
| Profit After Tax | -12 | -422 | -466 | -140 | -392 |
| Operating Profit After Depreciation | 187 | -171 | -49 | 89 | -281 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,457 | 2,226 | 2,392 | 2,584 | 2,093 |
| Total Non Current Assets | 3,418 | 3,200 | 3,257 | 3,410 | 3,056 |
| Total Current Assets | 1,990 | 1,668 | 1,475 | 2,388 | 1,839 |
| Total Assets | 5,408 | 4,868 | 4,732 | 5,798 | 4,895 |
| Total Shareholder's Fund | 2,763 | 1,796 | 1,753 | 2,212 | 1,606 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -14 | 188 | 71 | -93 | -563 |
| Net Cash Used In Investing Activities | -900 | -75 | -3 | -244 | 1,014 |
| Net Cash Used In Financing Activities | 486 | 346 | -236 | 430 | -480 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 965 | 888 | 782 | 738 | 743 |
| Total Expenses | 740 | 711 | 604 | 666 | 679 |
| Profit Before Tax | 189 | 67 | 91 | -109 | -22 |
| Profit After Tax | 164 | 61 | 82 | -108 | -45 |
| Operating Profit after Depreciation | 270 | 202 | 199 | 92 | 79 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 516 | 430 | 380 | 413 | 355 |
| Total Expenses | 355 | 317 | 267 | 282 | 249 |
| Profit Before Tax | 167 | 28 | 54 | 69 | 40 |
| Profit After Tax | 167 | 28 | 54 | 69 | 40 |
| Operating Profit after Depreciation | 216 | 140 | 143 | 156 | 120 |
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,783.55 | ₹4,27,933.39 |
| Divis Laboratories Ltd | ₹6,623.50 | ₹1,75,833.11 |
| Torrent Pharmaceuticals Ltd | ₹4,418.70 | ₹1,49,548.89 |
| Cipla Ltd | ₹1,400.70 | ₹1,13,154.89 |
| Zydus Lifesciences Ltd | ₹1,088.90 | ₹1,09,568.82 |
| Fund Name | AUM |
|---|---|
| Bank of India Small Cap Fund | 2.83% |
| Tata Small Cap Fund | 2.59% |
| Tata Large & Mid Cap Fund | 1.75% |
| HSBC Flexi Cap Fund | 1.25% |
| Mirae Asset ELSS Tax Saver Fund | 1.19% |
Sky Gold & Diamonds Ltd, Hindustan Zinc Ltd, HFCL Ltd and National Aluminium Company Ltd are among the other losers in the BSE's 'A' group today, 05 June 2026.
05 Jun 2026, 03:00 pm
Wockhardt shares tumbled 8.16% to Rs 1,976.35 on Tuesday as investors booked profits following a sharp rally triggered by the recent U.S. FDA approval of its novel antibiotic, ZAYNICH.
02 Jun 2026, 02:43 pm
Wockhardt Ltd is quoting at Rs 2201.1, up 8.35% on the day as on 12:44 IST on the NSE. The stock is up 50.14% in last one year as compared to a 4.86% jump in NIFTY and a 13.48% jump in the Nifty Pharma.
01 Jun 2026, 01:00 pm
Wockhardt surged 11.55% to Rs 2,266.10 on Monday after the company received approval from the U.S. Food and Drug Administration (FDA) for ZAYNICH.
01 Jun 2026, 09:35 am
Wockhardt rose 7.47% to Rs 1904 after the company received regulatory approval for its breakthrough antibiotic Zaynich in India.
29 May 2026, 10:45 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.